| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20000402 | HPV | ENSG00000164867.11 | protein_coding | NOS3 | No | No | 4846 | P29474 |
| TVIS20061493 | HPV | ENSG00000164867.11 | protein_coding | NOS3 | No | No | 4846 | P29474 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NOS3 |
|---|---|
| DrugBank ID | DB00360 |
| Drug Name | Sapropterin |
| Target ID | BE0000263 |
| UniProt ID | P29474 |
| Regulation Type | cofactor |
| PubMed IDs | 10075731; 10749876; 10924132; 10995244; 11009561; 12003347 |
| Citations | Heller R, Munscher-Paulig F, Grabner R, Till U: L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 1999 Mar 19;274(12):8254-60.@@Huang A, Vita JA, Venema RC, Keaney JF Jr: Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem. 2000 Jun 9;275(23):17399-406.@@Berka V, Tsai AL: Characterization of interactions among the heme center, tetrahydrobiopterin, and L-arginine binding sites of ferric eNOS using imidazole, cyanide, and nitric oxide as probes. Biochemistry. 2000 Aug 8;39(31):9373-83.@@Gorren AC, Bec N, Schrammel A, Werner ER, Lange R, Mayer B: Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. Biochemistry. 2000 Sep 26;39(38):11763-70.@@Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A: Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000 Sep 29;87(7):566-73.@@Gorren AC, Mayer B: Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines. Curr Drug Metab. 2002 Apr;3(2):133-57. |
| Groups | Approved; Investigational |
| Direct Classification | Biopterins and derivatives |
| SMILES | [H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O |
| Pathways | Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Hyperornithinemia with Gyrate Atrophy (HOGA); Sepiapterin Reductase Deficiency; DOPA-Responsive Dystonia; Alkaptonuria; Tyrosine Metabolism; Pterine Biosynthesis; Disulfiram Action Pathway; Hyperprolinemia Type II; Hyperphenylalaninemia Due to DHPR-Deficiency; Hyperphenylalaninemia Due to 6-Pyruvoyltetrahydropterin Synthase Deficiency (ptps); Hyperphenylalaniemia Due to Guanosine Triphosphate Cyclohydrolase Deficiency; L-Arginine:Glycine Amidinotransferase Deficiency; Tyrosinemia Type I; Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Tryptophan Metabolism; Doxorubicin Metabolism Pathway; Segawa Syndrome; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Hawkinsinuria; Dopamine beta-Hydroxylase Deficiency; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Ornithine Aminotransferase Deficiency (OAT Deficiency); Hyperprolinemia Type I; Monoamine Oxidase-A Deficiency (MAO-A); Tyrosinemia, Transient, of the Newborn; Nitric Oxide Signaling Pathway; Arginine and Proline Metabolism; Prolinemia Type II |
| PharmGKB | PA161990676 |
| ChEMBL | CHEMBL1201774 |
